Background. Pre-medication with clonidine reduces the requirement for volatile agents during general anaesthesia. This may also be true for anaesthesia with propofol, but the amount of dose reduction has not been measured. Because clonidine also affects cardiac output and thus regional blood flow it could alter the pharmacokinetics of propofol. This randomized, doubleblind placebo-controlled trial aimed to study the effect of clonidine pre-medication on dose requirement for propofol during lower extremity vascular surgery using the bispectral index (BIS) as a measure of anaesthetic depth.
Accepted for publication: April 13, 2005 Anaesthesia for lower limb revascularization can be complicated by pre-existing medical problems. Such patients may have ischaemic heart disease and hypertension, and be predisposd to myocardial ischaemia during and after surgery. Clonidine, an alpha 2 -adrenergic agonist with sedative and analgesic properties, 1 can reduce requirements for both volatile and i.v. anaesthetic agents. 2 3 It is safe in elderly 4 and high risk patients. 5 6 Clonidine may reduce adverse haemodynamic events and improve outcome in high risk patients. 6 Pre-treatment with clonidine reduces the requirement for propofol but it is not known if this is because of the sedative effect of clonidine 5 7 or a change in pharmacokinetics as seen with other alpha 2 -agonists. 8 Propofol kinetics are affected by changes in the distribution of blood volume, cardiac output, and hepatic blood flow. 9 10 The extent and nature of the dose-sparing effect of clonidine, in patients having vascular surgery using propofol anaesthesia, is not known.
The bispectral index (BIS, Aspect Medical Systems Inc., Newton, MA, USA) is a measure derived from the processed electroencephalograph (EEG). 11 The BIS has been shown to be superior to other processed EEG parameters in assessing depth of anaesthesia and sedation, 12 13 and is approved by the US Food and Drug Administration as a measure of hypnotic depth. It is useful in adjusting propofol effects to reduce total dosage and speed recovery. 14 We set out to measure the reduction in total propofol requirements after pre-medication with clonidine whilst ensuring equivalent depth of anaesthesia by continuous BIS measurement. We also wished to observe if this reduction was because of altered propofol pharmacokinetics or a direct sedative action of clonidine, by comparing actual and predicted plasma propofol concentrations.
Methods
After institutional ethics approval, written informed consent was obtained from 39 patients presenting for lower limb vascular surgery. Patients treated with clonidine, a-methyl dopa, sedatives or anticonvulsants, and those over 100 kg were excluded. This was a prospective, randomized, double-blind trial to compare the effect of pre-medication with clonidine or placebo. Our sample size calculation was based on our previously published variances in propofol steady state requirements 5 and a predicted treatment effect of 25%, using mean (SD) values of 4.0 (1.0) and 3.0 (1.0), a type I error 0.05 and a type II error of 0.80. The sample size estimation was 34 subjects with complete data. Subjects were randomly allocated to groups using a table of random numbers, with stratification according to current betablocker therapy. The dose of clonidine chosen to be studied, 3 mg kg À1 , was based on a previous study in vascular surgery that had demonstrated some beneficial effects at this dose. 6 Subjects were pre-medicated 1 h before surgery with an oral dose of the study drug, prepared by our hospital pharmacy clinical trials unit using sodium chloride and flavouring to mask allocation (either clonidine 3 mg kg À1 or placebo). After pre-medication, supplemental oxygen was administered. In the operating room venous and arterial cannulae were placed and standard monitoring (5-lead ECG, pulse oximetry, capnography and a peripheral nerve stimulator) applied. BIS was acquired using the BIS A1050 monitor and sensor (Aspect Medical Systems Inc., Newton, MA, USA), according to the manufacturer's instructions.
During pre-oxygenation, fentanyl 1 mg kg À1 i.v. was given and then anaesthesia induced with propofol using a target-controlled infusion pump (Diprifusor Ò , Sydney, Australia) with the target plasma concentration set to 4 mg ml À1 . The target value was raised by 1 mg ml
À1
increments until a BIS level of 45 or less was achieved. This was taken as time zero and the predicted plasma concentration was recorded. A further dose of fentanyl 1 mg kg À1 i.v. was then given. Neuromuscular block was achieved with mivacurium 0.2 mg kg À1 i.v. and the lungs ventilated with oxygen until the response to peripheral nerve stimulation was suppressed. After tracheal intubation, the patients were mechanically ventilated with a mixture of air and oxygen to obtain an end-tidal carbon dioxide partial pressure of 30-35 mm Hg. Spontaneous return of neuromuscular block was confirmed so that another indicator of adequate depth of anaesthesia-a lack of movement to surgical stimuli-could be incorporated into the technique. Anaesthesia was maintained by target-controlled infusion of propofol titrated to a BIS of 45. A lower BIS (35-40) was selected if movement occurred. Arterial blood samples were drawn at induction, 30, 60 and 90 min for plasma propofol concentration assay and to confirm normocapnia. Predicted plasma propofol concentrations were recorded from the target-controlled infusion pump, which calculates plasma and effect site concentrations using the Marsh pharmacokinetic model. 15 Towards the end of the procedure the anaesthetist aimed to adjust the propofol infusion to obtain a BIS of 60 at the time of application of dressings. The time to 1 mg ml À1 , predicted by the target-controlled infusion pump, and the time from end of surgery to eye opening, were recorded. Residual neuromuscular block was reversed using glycopyrrolate 0.4 mg and neostigmine 2.5 mg. Morphine 0.1-0.15 mg kg À1 was given i.v. as needed to obtain satisfactory analgesia. Patients were then transferred to the recovery room. Recovery times were measured from completion of wound dressing to obeying commands and to eligibility for discharge from the recovery room, the latter defined as a modified Aldrete score 16 of >9. Adverse events and total morphine requirements were recorded.
Intra-operative adverse haemodynamic events were managed according to the study protocol. In brief, 'escape medication' included glyceryl trinitrate infusion for hypertension, metaraminol or ephedrine for hypotension, metoprolol for tachycardia or ischaemia, glycopyrrolate for bradycardia, and fentanyl 1 mg kg À1 if rapid reduction of pain response was required (see Appendix).
Patients were reviewed on the day after surgery and assessed for adverse events or complications. Quality of recovery was measured using the QoR score, a nine-item score from zero to 18. 17 Arterial plasma samples were stored on ice, and later analysed for propofol with a high-performance liquid chromatography assay modified from the method of Plummer. 18 This assay is linear to 20 mg ml À1 , has a detection limit of 0.025 mg ml À1 and a coefficient of variation of 4.1% at 2 mg ml À1 .
Statistical analysis
The primary endpoints of time-averaged measured and predicted plasma propofol concentrations were compared using a repeated measures general linear model adjusted for baseline variables: age, gender and American Society of Anesthesiogists (ASA) physical status score. Times and morphine requirements were analysed using t-tests for parametric data.
Frequencies of adverse events were compared using the x 2 or Fisher's exact tests. All other comparisons used the Mann-Whitney U-test for non-parametric data. All analyses used SPSS for Windows v10.0 (SPSS Inc., Chicago, IL).
Our hypothesis was that a propofol-sparing effect of clonidine would be demonstrated if there were a relative reduction in the predicted propofol concentration, and so a one-sided P-value of <0.05 was considered significant; all other comparisons were two-sided.
Results
The groups were comparable for potentially confounding variables such as age, weight, gender, smoking history, co-morbidities, medications, and biochemical markers of liver and kidney function (Table 1 ). There was no significant difference in duration of surgery between the groups. Blood samples from four patients (one control, three clonidine) were not handled according to our protocol and assay method and were excluded from the primary endpoint analysis. The predicted plasma propofol concentrations from the target-controlled infusion pump following induction of anaesthesia (to BIS 45) was significantly different between groups, median (10th-90th centile): clonidine 4.0 (4.0-4.9) vs placebo 4.0 (4.0-6.5), U-test P<0.05.
Arterial concentrations of propofol at 30, 60, and 90 min were similar in the two groups ( Fig. 1 and Table 2 ), P=0.81. Comparing the predicted plasma propofol concentrations in the two groups, the predicted values in the clonidine group were 10% less than those in the placebo group (Fig. 2 and Table 2 ) (P<0.05). We did a correlational analysis between the actual and predicted plasma propofol concentrations at the three time periods to assess the accuracy of the targetcontrolled infusion pump algorithm (Table 3 ). In the placebo group there was a moderately strong correlation between the two variables but in the clonidine group the correlation decreased significantly over time.
Patients in both groups had equivalent depths of anaesthesia, judged by the time-averaged BIS readings during surgery (Table 4 ). There was no significant difference between the groups either for predicted time to awakening or actual time to obeying commands (Table 4 ). In the recovery room there was no difference between the groups, comparing time to fitness for discharge and QoR score. Patients receiving clonidine required significantly less morphine in the recovery room than patients in the placebo group ( Table 4 ). The QoR score on the day after surgery for patients given clonidine was significantly less than that of the placebo group (Table 4 ). Adverse event rates were similar between the groups (Table 5) , as were interventions There was no morbidity in either group during the study period, up to 24 h after surgery.
Discussion
We found that clonidine reduces propofol dose requirements. Clonidine reduced the dose of propofol required to achieve induction of anaesthesia. Unlike the effect of clonidine seen with inhalation anaesthetics, 1 2 this can be attributed to a pharmacokinetic effect. There was a difference between clonidine and placebo groups in their predicted and actual plasma propofol concentrations. The predicted concentration of propofol is calculated from a pharmacokinetic algorithm incorporated into the target-controlled infusion pump and so is affected by pharmacokinetic variables, 15 20 but in this study the actual measured plasma concentration of propofol reflected the dose required to obtain the desired anaesthetic effect, assessed by the BIS value. Thus, less rapid propofol administration will achieve the same BIS value in patients treated with clonidine.
The lack of difference between the groups with respect to assayed arterial plasma levels of propofol suggests that premedication with clonidine has no discernible pharmacodynamic effect in patients undergoing lower limb vascular surgery. Furthermore, in the placebo group there was a moderately strong correlation between the actual and predicted propofol concentrations, but the correlation decreased significantly over time in the clonidine group. This suggests that the pharmacokinetic algorithm used by the infusion pump failed to predict plasma concentrations correctly in patients treated with clonidine. The most plausible explanation is reduced hepatic clearance of propofol, because clonidine, like other alpha 2 -agonists, 1 reduces cardiac output and is likely to reduce hepatic blood flow. This will affect the volume of distribution of propofol and, because it is a high extraction drug, its clearance. 19 Propofol kinetics are affected by changes in blood volume distribution, cardiac output and hepatic blood flow. 9 10 19 Pulmonary uptake contributes to propofol clearance, 9 22 which may also be reduced with a decrease in cardiac output.
Although we noted predicted plasma propofol concentrations at induction we did not take arterial samples at this time, so we cannot assess the possible effect of clonidine on the initial volume of distribution of propofol. Nonetheless the mean predicted plasma concentration immediately after induction was significantly less in the study group, which suggests that the volume of distribution for propofol is reduced by pre-medication with clonidine. This supports the findings of others, for both propofol and thiopental. 5 8 The overall predicted plasma levels were some 30% less than the actual levels, highlighting the limited ability of the algorithm to predict propofol concentration in these patients, despite the Marsh model being a good kinetic model for target-controlled infusion of propofol. 15 The selection and titration of the target plasma concentration should be guided by the anaesthetist's assessment of anaesthetic depth, and BIS measurements should assist with this. 21 The finding that clonidine reduces immediate postoperative morphine requirements was expected in view of the established analgesic efficacy of clonidine and other centrally acting alpha 2 -agonists. 1 The sedative action of clonidine could delay discharge from the recovery room, but this was not observed in this study. Possible explanations include a limited sedative effect of the clonidine, the smaller propofol dose used, and less opioid requirements. In addition the Aldrete score may detect subtle signs of sedation caused by centrally acting alpha 2 -agonists. The rate of intra-operative adverse events was similar between the groups, which support previous experience. The trend towards increased frequency of hypotension and increased use of metaraminol may indicate the action of clonidine but may also have been influenced by the greater use of preoperative ACE-inhibitors in the study group.
We did not measure cardiac output or hepatic blood flow in this study, and can only speculate on clonidine's haemodynamic and pharmacokinetic effects. Despite randomization there were some differences between the groups that might have confounded the results. Surgical stimulation may cause arousal, an increase in BIS, and/or patient movement. This is an alternative explanation for more propofol administration in the placebo group, but does not account for the difference at induction nor the discrepancy between measured and predicted levels. More patients given clonidine were being treated with ACE-inhibitors, and generally had poorer ASA physical status scores. Although these differences were not statistically significant, the study group could be considered 'sicker' than the controls. In our statistical analysis, the general linear model adjusted for the ASA score, as well as age and gender, to reduce potential confounding. The finding of a reduced quality of recovery on the first postoperative day in this study was unexpected and is of concern. Further investigation of this issue is warranted. Although previous research has suggested a beneficial effect of clonidine on postoperative cardiovascular morbidity, 23 we did not find any effect in this study because of the short nature of the study period, a lack of power to detect such differences and the general lack of immediate postoperative complications.
We found that pre-medication with clonidine, 3 mg kg À1 , has a propofol-sparing effect in patients having vascular surgery. Unlike with inhalation anaesthetics, this is a pharmacokinetic effect, because there was a difference between predicted and actual plasma propofol concentrations. Clonidine may reduce cardiac output and hepatic blood flow, thus reducing propofol clearance.
